Health ❯Healthcare ❯Pharmaceuticals ❯Drug Development

Obesity Treatments

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Amgen plans to use lower starting doses with gradual escalation to improve tolerability ahead of expanded Phase 3 studies

Pfizer Halts Development of Oral Weight-Loss Pill After Liver Injury

Amgen Advances Weight-Loss Drug MariTide with Two Phase 3 Trials

FDA Approves Zepbound as First Medication for Obstructive Sleep Apnea in Adults with Obesity

Amgen's Weight-Loss Drug Shows Promise but Faces Investor Skepticism

Senate Grills Novo Nordisk CEO Over High U.S. Prices for Ozempic and Wegovy

Novo Nordisk's Obesity Pill Shows Modest Results, Stocks Drop